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###### KEY POINTS

•The EU PAS Register is a valuable resource to identify post authorization studies evaluating the effectiveness of risk minimisation measures in Europe, for which study protocols and reports are available.•This review summarizes the different routine and additional risk minimisation measures assessed in risk minimisation effectiveness studies.•This review provides an overview of the different process and outcome indicators used to assess the effectiveness of risk minimisation measures.•The majority of included studies did not pre‐specify a threshold for success.•This review provides evidence to support further development of the guidance.

1. INTRODUCTION {#pds4434-sec-0006}
===============

A new Directive and Regulation (Directive 2010/84/EU and Regulation (EU) No 1235/2010) was adopted by the European Parliament in December 2010 bringing significant changes in the safety monitoring of medicines across the European Union (EU). The new Pharmacovigilance (PhV) legislation, which came into effect in July 2012, introduced significant changes around PhV processes in Europe including the release of 16 guideline modules outlining good PhV practices (GVP).[1](#pds4434-bib-0001){ref-type="ref"}, [2](#pds4434-bib-0002){ref-type="ref"} Module XVI was first adopted in 2014 to provide guidance for the selection and evaluation of the effectiveness of risk minimisation measures (RMMs). In the same year, the Council for International Organizations of Medical Sciences Working Group IX published Practical Approaches to Risk Minimisation, which provides a framework for the evaluation of effectiveness of RMMs.[3](#pds4434-bib-0003){ref-type="ref"}

According to GVP module XVI, "RMMs are interventions intended to prevent or reduce the occurrence of adverse drug reactions associated with the exposure to a medicine or to reduce their severity or impact on the patient, should adverse reactions occur".[4](#pds4434-bib-0004){ref-type="ref"} Marketing authorization holders are required to monitor the outcome of RMMs, which are included in the risk management plan (RMP) or as a condition of market authorization. The RMMs may be classified as routine (rRMMs) or additional risk minimisation measures (aRMMs). The rRMMs are applicable to all medicinal products, and the majority of safety concerns are adequately addressed by rRMMs. When rRMMs may not be sufficient, aRMMs may be required to manage and mitigate the risk(s) that supplement rRMMs.[4](#pds4434-bib-0004){ref-type="ref"}

Effectiveness of RMMs is mainly evaluated for aRMMs but also sometimes for rRMMs. The effectiveness of RMMs can be evaluated by process and/or outcome indicators. Process indicators measure the extent to which a programme was implemented, whether the execution was as planned, and the impact on knowledge and behaviour of the target population. Outcome indicators provide an overall measure of the level of risk control achieved by RMM, for example, measuring rates of an adverse drug reaction or other safety‐related outcome.[4](#pds4434-bib-0004){ref-type="ref"} Evaluation of effectiveness of RMMs is important to manage the benefit‐risk balance of a medicinal product. Effectiveness of RMMs can be evaluated by using cross‐sectional survey studies and studies using secondary data sources.

The EU electronic Register of Post‐Authorization Studies (EU PAS Register) available through the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), launched in 2010, is a publicly available register of non‐interventional post‐authorization studies. The ENCePP activity report presented a rise in the registration of studies in the EU PAS Register from 20 studies in January 2012 and 440 in December 2014 to 968 in December 2016.[5](#pds4434-bib-0005){ref-type="ref"}, [6](#pds4434-bib-0006){ref-type="ref"}, [7](#pds4434-bib-0007){ref-type="ref"} The EU PAS Register includes study documents such as study protocol and report of the registered studies (based on status---planned, ongoing, or completed), which provides a unique opportunity to examine study details. According to the GVP VIII, marketing authorization holders are legally required to register non‐interventional post‐authorisation safety studies (PASS) imposed as an obligation (ie categories 1 and 2). It is also recommended to register all category 3 (required in the RMP) non‐interventional PASS and any other PASS to support transparency and facilitate exchange of information between different stakeholders.[8](#pds4434-bib-0008){ref-type="ref"} Therefore, the EU PAS Register is a valuable resource for PASS, including those evaluating the effectiveness of RMMs[9](#pds4434-bib-0009){ref-type="ref"} and those mandated by the European Medicines Agency. A review conducted by Gridchyna et al[10](#pds4434-bib-0010){ref-type="ref"} using MEDLINE and Embase included published studies evaluating the effectiveness of RMMs worldwide up to 2013, which was before GVP XVI was adopted. However, a comprehensive review of studies assessing the effectiveness of RMMs in European countries using EU PAS register is lacking including the studies initiated after GVP XVI. Therefore, the aim of this review is to describe and summarize PASS evaluating the effectiveness of RMMs in Europe and provide an overview of the RMMs and their effectiveness.

2. METHODS {#pds4434-sec-0007}
==========

This study was a qualitative review of RMM effectiveness studies using the EU PAS Register. All studies registered in the EU PAS Register from 2010 to 30 August 2016 were screened. Study titles were screened to identify those assessing the effectiveness of RMMs (hereinafter "RM effectiveness studies") using keywords such as "minimisation," "survey," "effectiveness," "drug utilization," "behaviour," "knowledge," "materials," and "physician." Studies were reviewed using information provided in the register. If there was any ambiguity of eligibility, the study protocol and/or report was reviewed. Studies were included if they evaluated the effectiveness of RMM(s), were conducted in at least one European country, and a report or executive summary was available in the EU PAS Register. The screening process and data extraction were conducted by 2 independent reviewers (P. V. and E. A.), and discrepancies were discussed and resolved. For the purpose of data extraction, the final version of study reports was used. When the study report was absent, the executive summary was used. All references were managed by using EndNote X7 (Thomson Reuters, USA). Table [1](#pds4434-tbl-0001){ref-type="table"} summarizes the variables abstracted from the included studies and their corresponding operational definitions.

###### 

Variables abstracted from studies evaluating the effectiveness of RMMs in Europe

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                 Operational Definition
  -------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study type                                               Surveys using primary data collection or studies using secondary data

  Target population (survey studies)                       Patients, specialists, GPs, or other HCPs

  Source for recruitment                                   Panel(s) or list(s) of prescribers used for recruitment

  Countries and no. of subjects/patients                   Participating countries in each study plus number of subjects/patients from each and in total

  Data source (secondary data studies)                     Secondary data sources used for evaluating RMM(s) including chart reviews.

  Risk and drug                                            Risk related to the drug for which the RMM(s) was implemented

  Indication                                               Indication of the drug for which the RMM is intended

  RMMs                                                     As per the GVP module XVI[4](#pds4434-bib-0004){ref-type="ref"}:\
                                                           rRMMs: SmPCs, package leaflet, labelling, pack size and design, legal status of the product\
                                                           aRMMs: Educational programmes/tools for patients or HCPs, controlled access programmes, controlled distribution systems, PPPs, and DHPC.

  Indicators                                               Process indicators: implementation and receipt of the RMM (eg educational materials reaching the target group and change in knowledge), understanding and awareness of HCPs or patients (eg knowledge gained by physicians about the importance of metabolic monitoring), and behavioural change (eg actual proportions of testing conducted by physicians).\
                                                           Outcome indicators: rates of an adverse drug reaction or other safety‐related outcome;\
                                                           (eg reduction in the incidence of risk under consideration after the implementation of RMM).\
                                                           *Note: One or more indicators could be assessed to evaluate the effectiveness of a single RMM*.[4](#pds4434-bib-0004){ref-type="ref"}

  Implementation date                                      Date of implementation of the RMM

  Study period                                             The period of data collection (for surveys); the period for which the data were analyzed (for studies using secondary data sources).

  Reported effectiveness (for each individual indicator)   Successful: the indicator assessing RMM achieved a pre‐specified threshold, the study concluded that the RMM was successful, no further RMM was required, RMM was sufficient, or used similar terms.\
                                                           Inconclusive: the indicator assessing RMM did not achieve a pre‐specified threshold, the study concluded that the results provided insufficient evidence, further analysis was required, or similar terms.\
                                                           *Note: these categories were ascertained solely based on the study results and conclusions in the study report*.
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: aRMM, additional risk minimisation measure; DHPC, Dear Healthcare Professional Communications; GP, general practitioner; GVP, good pharmacovigilance practices; HCP, health care professional; PPPs, pregnancy prevention programmes; rRMM, routine risk minimisation measure; RMM, risk minimisation measure; SmPC summary of product characteristics.

3. RESULTS {#pds4434-sec-0008}
==========

The screening process and the final number of studies included in the review are shown in Figure [1](#pds4434-fig-0001){ref-type="fig"} **.** Of the 872 studies registered in the EU PAS register from 2010 to 30 August 2016, 76 were RM studies with status planned, ongoing, or completed. In total, 19 RM effectiveness studies met the selection criteria and were included in this review.[11](#pds4434-bib-0011){ref-type="ref"}, [12](#pds4434-bib-0012){ref-type="ref"}, [13](#pds4434-bib-0013){ref-type="ref"}, [14](#pds4434-bib-0014){ref-type="ref"}, [15](#pds4434-bib-0015){ref-type="ref"}, [16](#pds4434-bib-0016){ref-type="ref"}, [17](#pds4434-bib-0017){ref-type="ref"}, [18](#pds4434-bib-0018){ref-type="ref"}, [19](#pds4434-bib-0019){ref-type="ref"}, [20](#pds4434-bib-0020){ref-type="ref"}, [21](#pds4434-bib-0021){ref-type="ref"}, [22](#pds4434-bib-0022){ref-type="ref"}, [23](#pds4434-bib-0023){ref-type="ref"}, [24](#pds4434-bib-0024){ref-type="ref"}, [25](#pds4434-bib-0025){ref-type="ref"}, [26](#pds4434-bib-0026){ref-type="ref"}, [27](#pds4434-bib-0027){ref-type="ref"}, [28](#pds4434-bib-0028){ref-type="ref"}, [29](#pds4434-bib-0029){ref-type="ref"}

![PRISMA flow diagram](PDS-27-695-g001){#pds4434-fig-0001}

3.1. Cross‐sectional surveys {#pds4434-sec-0009}
----------------------------

Eleven of the 19 included studies were cross‐sectional surveys of medical specialists, general practitioners, or other health care professional (HCPs,[12](#pds4434-bib-0012){ref-type="ref"}, [13](#pds4434-bib-0013){ref-type="ref"}, [14](#pds4434-bib-0014){ref-type="ref"}, [15](#pds4434-bib-0015){ref-type="ref"}, [16](#pds4434-bib-0016){ref-type="ref"}, [21](#pds4434-bib-0021){ref-type="ref"}, [23](#pds4434-bib-0023){ref-type="ref"}, [24](#pds4434-bib-0024){ref-type="ref"}, [25](#pds4434-bib-0025){ref-type="ref"} and 2 also included patients and caregivers.[22](#pds4434-bib-0022){ref-type="ref"}, [29](#pds4434-bib-0029){ref-type="ref"} Ten surveys had a cross‐sectional design, and one had a cross‐sectional quasi‐experimental design.[16](#pds4434-bib-0016){ref-type="ref"} All surveys were voluntary, and the participants were contacted/recruited by email, post, or via telephone to participate. Of the 11 surveys, 3 used a network or an established panel of HCPs,[12](#pds4434-bib-0012){ref-type="ref"}, [14](#pds4434-bib-0014){ref-type="ref"}, [15](#pds4434-bib-0015){ref-type="ref"} 4 targeted prescribers/potential prescribers who were sent RM materials,[13](#pds4434-bib-0013){ref-type="ref"}, [16](#pds4434-bib-0016){ref-type="ref"}, [21](#pds4434-bib-0021){ref-type="ref"}, [24](#pds4434-bib-0024){ref-type="ref"} 1 selected patients and caregivers who received RM materials,[29](#pds4434-bib-0029){ref-type="ref"} and the remaining 3 randomly selected prescribers or potential prescribers[22](#pds4434-bib-0022){ref-type="ref"}, [23](#pds4434-bib-0023){ref-type="ref"}, [25](#pds4434-bib-0025){ref-type="ref"} of which 1 also randomly selected treated patients.[22](#pds4434-bib-0022){ref-type="ref"} Eight were conducted as online surveys,[12](#pds4434-bib-0012){ref-type="ref"}, [13](#pds4434-bib-0013){ref-type="ref"}, [14](#pds4434-bib-0014){ref-type="ref"}, [15](#pds4434-bib-0015){ref-type="ref"}, [16](#pds4434-bib-0016){ref-type="ref"}, [21](#pds4434-bib-0021){ref-type="ref"}, [24](#pds4434-bib-0024){ref-type="ref"}, [25](#pds4434-bib-0025){ref-type="ref"} 1 involved face to face interviews of prescribing physicians and treated patients,[22](#pds4434-bib-0022){ref-type="ref"} 1 involved direct observation of patients and caregivers,[29](#pds4434-bib-0029){ref-type="ref"} and 1 was conducted via mail/telephone.[23](#pds4434-bib-0023){ref-type="ref"} The number of included countries ranged from 5 to 10 per survey except 1 survey that was conducted in 1 country.[23](#pds4434-bib-0023){ref-type="ref"} The countries most frequently included (≥5 studies) were as follows: the United Kingdom (10/11), Spain (9/11), Denmark (8/11), Germany (7/11), France (5/11), Netherlands (5/11), and Sweden (5/11). Figure [S1](#pds4434-supitem-0001){ref-type="supplementary-material"} shows the most frequently included EU countries in the surveys. Two of the 11 surveys also included non‐EU countries, which were Switzerland[13](#pds4434-bib-0013){ref-type="ref"}, [24](#pds4434-bib-0024){ref-type="ref"} and Hong Kong.[24](#pds4434-bib-0024){ref-type="ref"} The total number of participants in the 9 cross‐sectional surveys was based on quoted sample size estimations and ranged from 250 to 802, except 1 survey that involved 1 country that recruited 32 prescribers[23](#pds4434-bib-0023){ref-type="ref"} and 1 multi‐country study that recruited 40 patients or caregivers.[29](#pds4434-bib-0029){ref-type="ref"} The range of participants per country was 2 to 212.

Two of 11 surveys evaluated routine RMMs (SmPC)[12](#pds4434-bib-0012){ref-type="ref"}, [25](#pds4434-bib-0025){ref-type="ref"} and 9 evaluated aRMMs, which included Direct Healthcare Professional Communications (DHPC), physician\'s guides, checklists, educational materials, and patient alert cards. These RMMs were evaluated by using process indicators such as receipt of materials, understanding, knowledge, awareness, utilization, and behaviour. In total, there were 19 indicators assessing RMMs of which 13 were successful, ie effective. The remaining 6 indicators were inconclusive, of which 1 indicator was understanding and knowledge of the physician\'s guide,[13](#pds4434-bib-0013){ref-type="ref"} 1 was receipt of educational materials by HCPs,[16](#pds4434-bib-0016){ref-type="ref"} and the other 4 indicators were awareness, use, knowledge, and behaviour of using the checklist, Q&A brochure, and patient alert card.[21](#pds4434-bib-0021){ref-type="ref"} All countries planned for the survey eventually participated in the study except for 1 study where the survey was not initiated in one country (Sweden).[13](#pds4434-bib-0013){ref-type="ref"} Two studies planned to include both HCPs and patients; however, one study could not recruit patients owing to confidentiality regulations.[13](#pds4434-bib-0013){ref-type="ref"} Table [2](#pds4434-tbl-0002){ref-type="table"} summarizes the characteristics of the cross‐sectional surveys evaluating the effectiveness of RMMs and their reported effectiveness.

###### 

Characteristics of cross‐sectional survey studies

                                          No.                                                                                            Target Population                                                                                                    Source                                                 Countries                                       No. of Subjects                                                                         Drug                                                                                     Indication                                                                                                            Risk                                                                                               RMM Under Evaluation                                                                    Indicator Assessing the Effectiveness of RMM                                Indicator Type   RMM Implementation Time               Study Period                         Reported Effectiveness of RMM
  ----------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ----------------------------------------------- ----------------------------------------------------- ------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ---------------- ------------------------- -------------------------------------- ----------------------------------------------------
   1[15](#pds4434-bib-0015){ref-type="ref"}, [a](#pds4434-note-0004){ref-type="fn"}       GPs and specialists (paediatricians, child/adolescent psychiatrists, and other non‐paediatrician psychiatrists)                  Invitation to prescribers in the distribution list of DHPC and panel of HCPs              DK                                              100                                                                                  Atomoxetine                                                                                    ADHD                                                                                  Cardiovascular and cerebrovascular risk (paediatric patients)                               DHPC (SmPC changes, physician guide, associated checklists, and measurement recording chart)   (Wave 2) Reassess[g](#pds4434-note-0010){ref-type="fn"} knowledge, awareness, and adherence to changes      Process                2011                             2013                                       Successful
                                          SE                                                                                                    50                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          NL                                                                                                    100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                          ES                                                                                                    100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                          UK                                                                                                    200                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                         Total                                                                                                  550                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   2[14](#pds4434-bib-0014){ref-type="ref"}, [a](#pds4434-note-0004){ref-type="fn"}                                                 Specialists (psychiatrists)                                                                                           Panel of HCPs                                              DK                                              30                                                                                   Atomoxetine                                                                                    ADHD                                                                                     Cardiovascular and cerebrovascular risk (adult patients)                                    SmPC changes, physician guide, associated checklists, and measurement recording chart)                                  Knowledge, awareness, and adherence to changes                                  Process                2011                             2014                                       Successful
                                          SE                                                                                                    40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          NL                                                                                                    40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          ES                                                                                                    70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          UK                                                                                                    70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                         Total                                                                                                  250                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   3[16](#pds4434-bib-0016){ref-type="ref"}, [a](#pds4434-note-0004){ref-type="fn"}                              Specialists (psychiatrists and neurologists) GPs, and other HCPs                               Invitation to physicians who were potential prescribers in the distribution list of the materials    UK                                              100                                                                              Quetiapine fumarate                                                                           Anti‐psychotic                                                                              Weight gain, hyperglycaemia, and worsening of lipid profile                                                                   Educational materials                                                                           Receipt educational materials                                           Process                2012                             2013                                      Inconclusive
                                          DE                                                                                                    100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                          IT                                                                                                    100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                          RO                                                                                                    100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                          ES                                                                                                    100                                                                              Behaviour regarding monitoring of specific metabolic parameters                     Outcome[h](#pds4434-note-0011){ref-type="fn"}   Successful                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                          SE                                                                                                    100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                          HU                                                                                                    100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                          AT                                                                                                    100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                         Total                                                                                                  800                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   4[29](#pds4434-bib-0029){ref-type="ref"}, [b](#pds4434-note-0005){ref-type="fn"}                                                   Patients and caregivers                                                                              Patients or caregivers who received HAT pack                              AT                                              NS                                                                                   Romiplostim                                                                      Immune thrombo‐cytopenic purpura                                                                              Medication errors from self‐administration                                                                     Home administration training pack                                                                   Administered romiplostim correctly                                        Outcome              Dec 2012                7 Jul 2014 to 20 Jan 2016                             Successful
                                          BE                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          FR                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          DE                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          EL                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          NL                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          ES                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          UK                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                         Total                                                                                                  40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
   5[23](#pds4434-bib-0023){ref-type="ref"}, [c](#pds4434-note-0006){ref-type="fn"}                                                             GPs                                                                                  Random sample of physicians working in general practice                         DK                                              32                                                                     Cyproterone acetate and ethinilstradiol                   Moderate to severe androgen‐sensitive acne without seborrhoea and/or hirsutism in women of reproductive age            New safety precautions; adjustment of indication; contraindications; thromboembolic complications                                            DHPC and educational material                                                                                 Knowledge                                                     Process              Jun 2013                           2015                                       Successful
                                       **Total**                                                                                              **32**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
   6[13](#pds4434-bib-0013){ref-type="ref"}, [a](#pds4434-note-0004){ref-type="fn"}                                         Specialists (neurologists) and patients^e^                                                      Invitation to prescribers in the distribution list of the physician guide                DE                                              96                                                                                   Retigabine                                                                            Partial‐onset seizures                                              Prolongation of QT interval, voiding dysfunction/urinary retention, and hallucinations/confusion/psychotic disorders                                         Physician guide                                                                               Understanding and knowledge                                            Process          Not in the report                   2012--2013                                   Inconclusive
                                          DK                                                                                                    15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          UK                                                                                                    53                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          CH                                                                                                    23                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                       SE[e](#pds4434-note-0008){ref-type="fn"}                                                                                  ‐                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          ES                                                                                                    60                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          SK                                                                                                    28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          NO                                                                                                    19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                         Total                                                                                                  294                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   7[24](#pds4434-bib-0024){ref-type="ref"}, [a](#pds4434-note-0004){ref-type="fn"}                    Specialists (general neurology, neurosurgery, neuro‐psychiatry, and epileptologists)                           Invitation to prescribing and non‐prescribing physicians in the DHPC distribution list         BE                                              51                                                                                   Retigabine                                                                                   Epilepsy                                                                             Eye disorders, ie pigment changes, skin, and subcutaneous disorders                                                                        DHPC                                                                                      Awareness and knowledge                                              Process              Jun 2013                        2014--2015                                    Successful
                                          HK                                                                                                     2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          NO                                                                                                    17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          SK                                                                                                    66                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          ES                                                                                                    186                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                          CH                                                                                                    29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          UK                                                                                                    63                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                         Total                                                                                                  414                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   8[21](#pds4434-bib-0021){ref-type="ref"}, [a](#pds4434-note-0004){ref-type="fn"}    Specialists (critical care, haematology, infectious diseases, intensive care, microbiology, and oncology, transplant)                             Invitation to prescribers who received the RMMs                             AT                                              2                                                                                   Voriconazole                                                                              Fungal infections                                                                            Phototoxicity, squamous cell carcinoma, and hepatic toxicity                                         HCP checklist, HCP question and answer brochure, and patient alert card                                                       Awareness (receipt)                                                Process              Apr 2014                        2015--2016                Inconclusive[i](#pds4434-note-0012){ref-type="fn"}
                                          DK                                                                                                     5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          FR                                                                                                    42                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          DE                                                                                                    16                                                                                                         Utilization                                               Process                                         Inconclusive                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                          HU                                                                                                    13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          IE                                                                                                     7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          IT                                                                                                    14                                                                                                          Knowledge                                                Process                                         Inconclusive [i](#pds4434-note-0012){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                          NL                                                                                                    21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          ES                                                                                                    191                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                          UK                                                                                                    21                                                                                                          Behaviour                                                Process                                         Inconclusive                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                         Total                                                                                                  332                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   9[12](#pds4434-bib-0012){ref-type="ref"}, [a](#pds4434-note-0004){ref-type="fn"}                   Specialists (HIV, infectious disease, and genito‐urinary), GPs, nurses, and pharmacists                                                       Panels of HIV prescribers                                        AT/DE                                           101                                                    Rilpivirine and Emtricitabine/Rilpivirine/Tenofovir disoproxil fumarate                                                 HIV‐1 infection                                                  Lack of therapeutic effect potentially leading to development of resistance when taking the drug without food/meal                SmPC[f](#pds4434-note-0009){ref-type="fn"} (prescribing information)                                                           Understanding                                                   Process           Not applicable                        2014                                       Successful
                                         BE/NL                                                                                                  49                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          FR                                                                                                    71                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          UK                                                                                                    73                                                                                           Utilization of prescribing instructions                                 Process                                         Successful                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                          NO                                                                                                     6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          DK                                                                                                     7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          SE                                                                                                    16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                         Total                                                                                                  323                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   10[25](#pds4434-bib-0025){ref-type="ref"}, [a](#pds4434-note-0004){ref-type="fn"}                                                 Specialists (oncologists)                                                 Random sample of oncologists selected from the master list for each country and stratified by region  DK                                              NS                                                                                    Denosumab                                                           Anti‐resorptive therapy in patients with advanced cancer                                                                           Osteonecrosis of the jaw                                                                          SmPC[f](#pds4434-note-0009){ref-type="fn"}                                                                          Knowledge                                                     Process           Not‐ applicable       (2 rounds) 2013--2014 and 2013--2015                       Successful
                                          FI                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          FR                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          DE                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          IT                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          NO                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          ES                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          SE                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          UK                                                                                                    NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                         Total                                                                                                  420                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                     11^22^ [d](#pds4434-note-0007){ref-type="fn"}                                                              Specialists (cardiologists) and GPs                                                                             Prescribing HCPs randomly selected                                   BG                                              58                                                                                   Dabigatran                                                                                     SPAF                                                                                                             Bleeding                                                             Prescriber guide and patient alert card (within the educational pack to physicians)                                         Receipt and distribution to patients                                       Process          Not in the report                      2015                                       Successful
                                          CZ                                                                                                    64                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          DK                                                                                                     1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          FR                                                                                                    50                                                                                      Knowledge and recommendations to their AF patients                           Process                                         Successful                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                          DE                                                                                                    69                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          SK                                                                                                    46                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          ES                                                                                                    62                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          UK                                                                                                    61                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                         Total                                                                                                  411                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                       Patients                                                                                 Treated patients randomly selected                                                                                              BG                                                   103                                             Patient alert card (within the pack)                                                   Receipt                                                                                     Process                                                                                                      Not in the report                                                                                                 2015                                                                                             Successful                                                                                                                                  
                                          CZ                                                                                                    108                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                          DK                                                                                                    43                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          FR                                                                                                    92                                                                                                        Understanding                                              Process                                         Successful                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                          DE                                                                                                    212                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                          SK                                                                                                    59                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          ES                                                                                                    118                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                          UK                                                                                                    67                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                         Total                                                                                                  802                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

Online survey.

Data collected using direct observation.

Survey by mail or telephone.

Face to face survey.

Initially planned but not included in the study after challenges encountered.

Routine risk minimisation measure.

First risk minimisation effectiveness assessment survey was conducted in 2012 (Wave 1).

As reported in the study.

Successful for most but not all risks.

Abbreviations: ARV, antiretroviral; ADHD, attention deficit hyperactivity disorder; AF, Atrial Fibrillation; DHPC, Direct Healthcare Professional Communication; GPs, general practitioners; HIV‐1, human immunodeficiency virus type 1; NS, not specified; RMMs, risk minimisation measures; SmPC, summary of product characteristics; SPAF, stroke prevention for atrial fibrillation; HAT, home administration training.

Countries: AT, Austria; BE, Belgium; BG, Bulgaria; HR, Croatia; CZ, Czech Republic; DK, Denmark; EE, Estonia; FI, Finland; FR, France; EL, Greece; DE, Germany; HU, Hungary; HK, Hong Kong; IE, Ireland; IT, Italy; LV, Latvia; LT, Lithuania; LU, Luxembourg; NL, Netherlands; PL, Poland; PT, Portugal; RO, Romania; SI, Slovenia; SK, Slovakia; ES, Spain; SE, Sweden; CH, Switzerland; UK, United Kingdom.

3.2. Studies using secondary data sources {#pds4434-sec-0010}
-----------------------------------------

Eight of the 19 included studies used secondary data sources for RM effectiveness studies.[11](#pds4434-bib-0011){ref-type="ref"}, [17](#pds4434-bib-0017){ref-type="ref"}, [18](#pds4434-bib-0018){ref-type="ref"}, [19](#pds4434-bib-0019){ref-type="ref"}, [20](#pds4434-bib-0020){ref-type="ref"}, [26](#pds4434-bib-0026){ref-type="ref"}, [27](#pds4434-bib-0027){ref-type="ref"}, [28](#pds4434-bib-0028){ref-type="ref"}, [29](#pds4434-bib-0029){ref-type="ref"} Two of the 8 studies involved chart review using electronic medical records.[11](#pds4434-bib-0011){ref-type="ref"}, [17](#pds4434-bib-0017){ref-type="ref"} The remaining 6 studies used multiple health care databases, which included Aarhus University Research Database and population health registers from Denmark, Clinical Practice Research Datalink (CPRD) from the United Kingdom, Integrated Primary Care Information , Dutch PHARMO general practitioner database from the Netherlands, and the Emilia Romagna regional database from Italy. The countries most frequently included (≥2 studies) were United Kingdom (7/8 studies), Denmark (2/8 studies), Germany (2/8 studies), and Netherlands (2/8 studies). Among the 7 studies involving United Kingdom, 5 studies used CPRD.[18](#pds4434-bib-0018){ref-type="ref"}, [19](#pds4434-bib-0019){ref-type="ref"}, [20](#pds4434-bib-0020){ref-type="ref"}, [26](#pds4434-bib-0026){ref-type="ref"}, [27](#pds4434-bib-0027){ref-type="ref"} Table [3](#pds4434-tbl-0003){ref-type="table"} summarizes the characteristics of RM effectiveness studies using secondary data sources, and Figure [S2](#pds4434-supitem-0002){ref-type="supplementary-material"} shows the countries where these studies were conducted. Seven were retrospective cohort studies,[11](#pds4434-bib-0011){ref-type="ref"}, [18](#pds4434-bib-0018){ref-type="ref"}, [19](#pds4434-bib-0019){ref-type="ref"}, [20](#pds4434-bib-0020){ref-type="ref"}, [26](#pds4434-bib-0026){ref-type="ref"}, [27](#pds4434-bib-0027){ref-type="ref"}, [28](#pds4434-bib-0028){ref-type="ref"} and 1 was cross sectional.[17](#pds4434-bib-0017){ref-type="ref"} All 7 retrospective studies were drug utilization studies of which 3 had a pre‐post design.[11](#pds4434-bib-0011){ref-type="ref"}, [19](#pds4434-bib-0019){ref-type="ref"}, [26](#pds4434-bib-0026){ref-type="ref"} The total sample size in the 7 retrospective cohort studies ranged from 687 to 34 975.[11](#pds4434-bib-0011){ref-type="ref"}, [18](#pds4434-bib-0018){ref-type="ref"}, [19](#pds4434-bib-0019){ref-type="ref"}, [20](#pds4434-bib-0020){ref-type="ref"}, [26](#pds4434-bib-0026){ref-type="ref"}, [27](#pds4434-bib-0027){ref-type="ref"}, [28](#pds4434-bib-0028){ref-type="ref"} One cross‐sectional study used electronic medical records from the IMS® Disease Analyzer and included 294 subjects.[17](#pds4434-bib-0017){ref-type="ref"}

###### 

Characteristics of studies using secondary data sources

                                          No.                                                               Design                        Countries                                                   No. of Patients                                                                           Database/Data Source                                                                                       Drug                                                                                    Indication                                                                                            Risk                                                                            RMMs Under Evaluation                                         Indicator Assessing the Effectiveness of RMMs     Indicator Type    RMM Implementation Time                 Study Period                 Reported Effectiveness
  ----------------------------------------------------------------------------------- --------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------------- ---------------- ------------------------- ------------------------------------------- -------------------------------------------------------------------------------------------------
                     12[20](#pds4434-bib-0020){ref-type="ref"} ^a^                             Retrospective cohort study (DUS)           DK                                                          2321                                                                                      Population health registries of 2 northern regions                                           Rosiglitazone containing products                                                              Type 2 diabetes mellitus                                                                        Risk of cardiovascular outcomes                              Labelling changes[b](#pds4434-note-0016){ref-type="fn"} and suspension from EU markets        Utilization dynamics                              Outcome                 23 Sep 2010                        2000--2010                  [a](#pds4434-note-0015){ref-type="fn"}Limited information[a](#pds4434-note-0015){ref-type="fn"}
                                          UK                                                                25 428                        GPRD (CPRD)                                                 \% of users with contraindications                                                        Outcome                                                                          Limited information[a](#pds4434-note-0015){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                        Glycaemic control and other parameters                                              Outcome                       Limited information[a](#pds4434-note-0015){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                         Total                                                              27 749                        ‐                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                       13[18](#pds4434-bib-0018){ref-type="ref"}                               Retrospective cohort study (DUS)           UK[c](#pds4434-note-0017){ref-type="fn"}                    323                                                                                       GPRD (CPRD)                                                                                            Isotretinoin                                             Severe nodular acne vulgaris that is unresponsive to other, first‐line therapies                                                  Teratogenic effects                                                                Pregnancy prevention programme                                    Prescription during pregnancy                     Outcome              Not in the report                Jan 2004 to Dec 2010             Inconclusive
                    UK Wales[d](#pds4434-note-0018){ref-type="fn"}                                             ‐                          SAIL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                          IT                                                                 5882                         Emilia Romagna regional database                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                         IT^d^                                                                 ‐                          Tuscany regional database                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                       DK[d](#pds4434-note-0018){ref-type="fn"}                                                ‐                          Statistik Denmark                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                         Total                                                               6205                         ‐                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                       14[19](#pds4434-bib-0019){ref-type="ref"}                       Retrospective cohort study (DUS; pre/post‐design)  DK                                                          878 new users                                                                             AURD                                                                                                   Pioglitazone                                                               Type 2 diabetes mellitus (secondline therapy)                                                                     Bladder cancer                                          DHPC---to restrict use in patients without known risk factors of bladder cancer            Drug utilization patterns before and after DHPC   Outcome                Jul‐Aug 2011                 1 Jan 2005 to 2 Feb 2012           Limited information
                                          NL                                                             789 new users                    IPCI                                                        Events, ADRs, and diabetes control in discontinued patients after DHPC                    Outcome                                                                                          1 Jan 2007 to 30 Jun 2012                                                                     Limited information                                                                                                                                                                                                                                                                                                                                                                              
                                          UK                                                           33 308 new users                   CPRD (former GPRD)                                          Contraindications, events, ADRs, and diabetes control in prevalent/new users after DHPC   Outcome                                                                                          1 Jan 2000 to 31 Mar2012                                                                      Limited information                                                                                                                                                                                                                                                                                                                                                                              
                                         Total                                                              34 975                        ‐                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
   15[26](#pds4434-bib-0026){ref-type="ref"}, [a](#pds4434-note-0015){ref-type="fn"}   Retrospective cohort study (DUS; pre/post‐design)  UK                                                          32 947                                                                                    CPRD (former GPRD)                                                                                     Pioglitazone                                                              Type 2 diabetes mellitus (second‐line therapy)                                        Bladder cancer, heart failure, and need of monitoring of therapy benefits                   EU SmPC[b](#pds4434-note-0016){ref-type="fn"} and unspecified RMMs                  Bladder cancer                                    Outcome                  Jul 2011                       Not in the report              [a](#pds4434-note-0015){ref-type="fn"}Limited information[a](#pds4434-note-0015){ref-type="fn"}
                        Regular monitoring of therapy benefits                                              Outcome                       Limited information[a](#pds4434-note-0015){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                         Total                                                              32 947                        ‐                                                           Prevalent heart failure                                                                   Outcome                                                                          Limited information[a](#pds4434-note-0015){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                      
   16[28](#pds4434-bib-0028){ref-type="ref"}, [a](#pds4434-note-0015){ref-type="fn"}           Retrospective cohort study (DUS)           NL                                                          2238                                                                                      Dutch PHARMO GP database                                                                               Pioglitazone                                                              Type 2 diabetes mellitus (second‐line therapy)                                                            Bladder cancer and heart failure                                     SmPC changes[b](#pds4434-note-0016){ref-type="fn"} and unspecified RMMs                Contraindications                                 Outcome                  Jul 2011                        2003--2011/2012               Successful
                                      Utilization                                                           Outcome                       Successful                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                Monitoring frequencies                                                      Outcome                       Successful                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                         Total                                                               2238                         ‐                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
   17[27](#pds4434-bib-0027){ref-type="ref"}, [a](#pds4434-note-0015){ref-type="fn"}           Retrospective cohort study (DUS)           UK                                                          1808 new‐users; 12 986 prevalent users                                                    CPRD (former GPRD)                                                                                     Pioglitazone                                                              Type 2 diabetes mellitus (second‐line therapy)                                         Heart failure, bladder cancer, acroscopic hematuria, and first‐line use                 Label change[b](#pds4434-note-0016){ref-type="fn"} and unspecified RMMs                First‐line use                                    Outcome                  Jul 2011                  21 Jul 2011 to 21 Dec 2013          Successful
                              Incidence of heart failure                                                    Outcome                       Limited information[a](#pds4434-note-0015){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                    Bladder cancer                                                          Outcome                       Successful                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                 Macroscopic hematuria                                                      Outcome                       Limited information[a](#pds4434-note-0015){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                 Monitoring of glucose                                                      Outcome                       Limited information[a](#pds4434-note-0015){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                         Total                                                              14 794                        ‐                                                           Creatinine                                                                                Outcome                                                                          Limited information[a](#pds4434-note-0015){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                       18[11](#pds4434-bib-0011){ref-type="ref"}                       Retrospective cohort study (DUS; pre/post‐design)  AT                                                          101                                                                                       Electronic medical records or paper registries from hospitals in each country                           Tigecycline                          Complicated intra‐abdominal Infection, complicated skin or soft tissue infection, and excluding diabetic foot infection             Super‐infection, lack of efficacy, and off‐label use              Changes to the SmPC[b](#pds4434-note-0016){ref-type="fn"}, DHPC, and educational material for HCPs  Incidence of superinfection                       Outcome                  Feb 2011           Pre: Feb 2010--2011; Post: Feb 2012--2013  Successful
                                          DE                                                                  315                         Incidence of lack of efficacy cases                         Outcome                                                                                   Successful                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                          EL                                                                  27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                          UK                                                                  244                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                       IT[d](#pds4434-note-0018){ref-type="fn"}                                                ‐                          Incidence of off‐label indication use                       Outcome                                                                                   Successful                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                       ES[d](#pds4434-note-0018){ref-type="fn"}                                                ‐                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                         Total                                             687[e](#pds4434-note-0019){ref-type="fn"}      ‐                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                       19[17](#pds4434-bib-0017){ref-type="ref"}                                     Cross‐sectional study                DE                                                          1451                                                                                      IMS disease analyzer (retrospectively collected EMRs)                                               Quetiapine fumarate                                                                           Antipsychotic                                                               Weight gain, hyperglycaemia, and worsening of lipid profile                                                Educational materials                                         Evaluation and metabolic monitoring of patients   Outcome                 Early 2012                    13 Feb to 31 Aug 2012            Inconclusive in DE
                                          UK                                                                  887                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                11 Jan to 31 July 2012                                                 Successful in UK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                         Total                                                               2338                         ‐                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

Only executive summary available.

Routine risk minimisation measure.

Feasibility study.

Initially planned but not included in the study after challenges encountered.

Sample size differed according to indicators evaluated.

Abbreviations: ADR, adverse drug reaction; AURD, Aarhus University Research Database; CPRD, Clinical Practice Research Datalink; DHPC, Direct Healthcare Professional Communication; EMRs, Electronic Medical Records; DUS, drug utilization study; GPRD, General Practice Research Datalink; IPCI, Integrated Primary Care Information; SAIL, Secure Anonymised Information Databank; SmPC, Summary of Product Characteristics; EU, European Union.

Countries: AT, Austria; BE, Belgium; DK, Denmark; FR, France; EL, Greece; DE, Germany; IT, Italy; NL, Netherlands; ES, Spain; UK, United Kingdom.

All 8 studies evaluated aRMMs that included educational materials, a pregnancy prevention programme, DHPCs; 5 studies also evaluated changes in rRMMs (SmPC/label changes).[11](#pds4434-bib-0011){ref-type="ref"}, [20](#pds4434-bib-0020){ref-type="ref"}, [26](#pds4434-bib-0026){ref-type="ref"}, [27](#pds4434-bib-0027){ref-type="ref"}, [28](#pds4434-bib-0028){ref-type="ref"} These RMMs were evaluated by using outcome indicators. Of the total of 23 indicators, success was achieved with 8 indicators,[11](#pds4434-bib-0011){ref-type="ref"}, [27](#pds4434-bib-0027){ref-type="ref"}, [28](#pds4434-bib-0028){ref-type="ref"} 1 was inconclusive,[18](#pds4434-bib-0018){ref-type="ref"} 1 study with 1 indicator achieved success in 1 country but was inconclusive in the other included country (partially successful),[17](#pds4434-bib-0017){ref-type="ref"} and success could not be determined due to limited reported information with remaining 13 indicators.[19](#pds4434-bib-0019){ref-type="ref"}, [20](#pds4434-bib-0020){ref-type="ref"}, [26](#pds4434-bib-0026){ref-type="ref"}, [27](#pds4434-bib-0027){ref-type="ref"} In general, the indicators examined changes in incidence of the risk under evaluation (n = 7), monitoring parameters (n = 7), drug use patterns (n = 5), pregnancy prevention (n = 1), and prescribing in patients with contraindications (n = 3). Three studies with 9 indicators used pre‐post design to evaluate effectiveness.[11](#pds4434-bib-0011){ref-type="ref"}, [19](#pds4434-bib-0019){ref-type="ref"}, [26](#pds4434-bib-0026){ref-type="ref"} Two studies were unable to use the planned data sources due to various challenges encountered.[11](#pds4434-bib-0011){ref-type="ref"}, [18](#pds4434-bib-0018){ref-type="ref"} These include medical records from Spain that required informed consent from all patients (deceased and living), medical records from Italy where physicians declined to participate owing to informed consent form requirements or lack of staff, Secure Anonymised Information Databank (SAIL) from the United Kingdom where ethics approval could not be obtained, General Practice Research Database where the study had to be carried out as feasibility study because Independent Scientific Advisory Committee claimed the study was not feasible, Tuscany regional database in Italy where the data could not be obtained in time, and Statistik Denmark from Denmark where it was identified that the required information for the study was limited.

3.3. Threshold {#pds4434-sec-0011}
--------------

Two of 11 cross‐sectional surveys established a pre‐defined threshold for success, which was set as at least 80% of correct responses.[12](#pds4434-bib-0012){ref-type="ref"}, [21](#pds4434-bib-0021){ref-type="ref"} In one of the 2 studies, that defined threshold a priori, the selection of threshold was considered subjective and not based on prior knowledge, or established scientific criteria, and was also acknowledged by European Medicines Agency in their interactions.[21](#pds4434-bib-0021){ref-type="ref"} In the remaining 9 studies, a majority of participants correctly achieving the desired result were considered as successful. No study using secondary data sources defined success; however, 3 of the 8 studies used a pre‐post implementation of RMM design, in which success was judged by reduction in risk post RMM implementation.[11](#pds4434-bib-0011){ref-type="ref"}, [19](#pds4434-bib-0019){ref-type="ref"}, [26](#pds4434-bib-0026){ref-type="ref"}

4. DISCUSSION {#pds4434-sec-0012}
=============

This review provides a qualitative overview of 11 cross‐sectional survey studies and 8 studies using secondary data evaluating the effectiveness of RMMs in EU using the EU PAS Register. A substantial number (\~90%) of the included studies evaluated aRMMs. Most aRMMs communicated label changes. Indicators included process and/or outcome to assess the effectiveness of aRMMs in accordance with GVP module XVI; half of them achieved success. Typically cross‐sectional survey studies used process indicators to assess the effectiveness of RMMs, and studies using secondary data used outcome indicators of various kinds. While secondary data source studies mainly assessed label changes with or without DHPCs and educational materials in few cases, survey studies mostly evaluated educational materials and DHPCs. Two survey studies assessed the existing label to determine whether further actions are needed.[12](#pds4434-bib-0012){ref-type="ref"}, [25](#pds4434-bib-0025){ref-type="ref"} This review demonstrates the utilization of secondary data sources to conduct RM effectiveness studies in countries with health care data sources that are suitable for particular outcome measure. The United Kingdom was the most frequently selected country, included in all but 2 studies. Other frequent countries included Denmark, Spain, Germany, and Netherlands. More than two thirds of studies were multi‐country, and sample sizes varied considerably across studies. The choice of countries participating in RM effectiveness studies seems to be limited to a few that are consistently included in most evaluations (eg United Kingdom). This is particularly the case in studies using secondary data sources, hindering the extrapolation of results to other health care systems. It was also found that some countries initially planned to participate but were eventually excluded owing to challenges, and therefore, conducting feasibility assessment is very important. In a systematic review conducted by Gridchyna et al[10](#pds4434-bib-0010){ref-type="ref"} using MEDLINE and Embase, 65 published RM effectiveness studies worldwide were identified up to 2013; 19 of these were from Europe. None of the studies overlapped with those in this review, which was based on final study reports available in the EU PAS Register. Therefore, the results from this review supplement those presented by Gridchyna et al.

Data quality and completeness in cross‐sectional surveys is mostly dependent on the development and appropriateness of the survey questionnaire (eg cognitive interviews and linguistic validation) and the data collection method. Two in every 3 surveys in the review used online questionnaires, providing real‐time data efficiently and allowing the implementation of controls and data checks to enhance data quality (eg questions provided in a sequence, skipping patterns, and restricting changes). Also, survey studies are prone to recall, self‐report, and non‐response biases if participants who participate differ from those who do not, resulting in a non‐representative sample. However, outcomes for which studies using secondary data might not be feasible, survey studies can provide valuable insights. Few survey studies had disproportionate participation across countries, which may be a reflection of the usage of the product or difficulties identifying prescribers in these countries that could affect the generalizability of the results.[12](#pds4434-bib-0012){ref-type="ref"}, [21](#pds4434-bib-0021){ref-type="ref"}, [24](#pds4434-bib-0024){ref-type="ref"} Some studies encountered operational challenges such as access, approval, feasibility, and resources, which hindered their participation.[11](#pds4434-bib-0011){ref-type="ref"}, [18](#pds4434-bib-0018){ref-type="ref"} Sample size or the number of participants in survey studies can affect the results of the study if targeted number of participants is not achieved. Two studies in the review did not reach the pre‐specified sample size[13](#pds4434-bib-0013){ref-type="ref"}, [21](#pds4434-bib-0021){ref-type="ref"}; of which one only recruited half of the planned number of participants and was inconclusive.[21](#pds4434-bib-0021){ref-type="ref"} Recruitment might be challenging in surveys and may limit generalizability (eg 1 survey study planned in patients and HCPs ‐ the patient survey part was excluded owing to confidentiality regulations).[13](#pds4434-bib-0013){ref-type="ref"} For studies using secondary data, quality of the data sources as well as validation of the outcomes is important to consider. Threshold for success of a RMM should be defined on a case‐by‐case basis considering the outcome, and a rationale for selection of the threshold should ideally be reported. While there should be strict threshold criteria for adverse events, for example, no pregnancy during exposure to teratogenic drugs, in other cases, the event cannot be mitigated and the RMM will only result in a reduction of the severity or aim to promote better control through monitoring or promoting action. However, few studies in this review reported a threshold for success and results were difficult to interpret for the others, highlighting the need for further guidance.

One potential approach for RM effectiveness could include survey component to evaluate process indicator(s) and secondary use of data to evaluate outcome indicator(s). One such example is included in this review, where physician\'s self‐reported behaviour (process indicator) was assessed through a cross‐sectional survey and monitoring of patients by physicians (outcome indicator) was assessed by using secondary data.[16](#pds4434-bib-0016){ref-type="ref"}, [17](#pds4434-bib-0017){ref-type="ref"} As these were 2 separate studies, no correlation of process and outcome indicators was reported.

The strengths of this review include the use of the EU PAS Register to review RM effectiveness studies and the availability of the detailed study reports. This review provides insights into RM effectiveness studies conducted in the EU with a good representation of potential study designs, target populations (physicians, nurses, pharmacists, and patients), practice settings (general practice and secondary care), RMMs (DHPC, pregnancy prevention programme, educational materials, and label changes), countries, data sources, and indicators (process and outcomes). This review also had some limitations. Firstly, the selection of studies may have been affected by publication bias. It is possible that category 3 PASS studies, which are required in the RMP or other PASS conducted voluntarily, for which registration in the EU PAS Register is not mandatory, might have been missed if not registered. However, out of the total 19 studies, 12 were category‐3[12](#pds4434-bib-0012){ref-type="ref"}, [13](#pds4434-bib-0013){ref-type="ref"}, [14](#pds4434-bib-0014){ref-type="ref"}, [16](#pds4434-bib-0016){ref-type="ref"}, [17](#pds4434-bib-0017){ref-type="ref"}, [21](#pds4434-bib-0021){ref-type="ref"}, [23](#pds4434-bib-0023){ref-type="ref"}, [24](#pds4434-bib-0024){ref-type="ref"}, [26](#pds4434-bib-0026){ref-type="ref"}, [27](#pds4434-bib-0027){ref-type="ref"}, [28](#pds4434-bib-0028){ref-type="ref"}, [29](#pds4434-bib-0029){ref-type="ref"} of which 10 were requested by regulatory authorities,[12](#pds4434-bib-0012){ref-type="ref"}, [14](#pds4434-bib-0014){ref-type="ref"}, [16](#pds4434-bib-0016){ref-type="ref"}, [17](#pds4434-bib-0017){ref-type="ref"}, [21](#pds4434-bib-0021){ref-type="ref"}, [23](#pds4434-bib-0023){ref-type="ref"}, [26](#pds4434-bib-0026){ref-type="ref"}, [27](#pds4434-bib-0027){ref-type="ref"}, [28](#pds4434-bib-0028){ref-type="ref"}, [29](#pds4434-bib-0029){ref-type="ref"} 3 studies were conducted by regulatory authorities,[18](#pds4434-bib-0018){ref-type="ref"}, [19](#pds4434-bib-0019){ref-type="ref"}, [20](#pds4434-bib-0020){ref-type="ref"} 1 was category‐2,[11](#pds4434-bib-0011){ref-type="ref"} and the remaining 3 were conducted voluntarily.[15](#pds4434-bib-0015){ref-type="ref"}, [22](#pds4434-bib-0022){ref-type="ref"}, [25](#pds4434-bib-0025){ref-type="ref"} Publication of these RM effectiveness studies should be encouraged as it adds important public health value. Additionally, 57 RM studies were excluded in the selection process because they were planned or ongoing---5 of these had status "finalized" but results were unavailable. Secondly, there were many studies with one or more risks and RMMs, but it was not possible to report on them separately as effectiveness was reported per indicator for the RMM(s) as a whole.. Thirdly, the success or effectiveness of the RMMs is based on the reported results and conclusions; however, its regulatory impact and consequences are unknown. Fourthly, only a summary report or abstract was available for 5 of the 19 included studies from which limited information could be extracted.[20](#pds4434-bib-0020){ref-type="ref"}, [26](#pds4434-bib-0026){ref-type="ref"}, [27](#pds4434-bib-0027){ref-type="ref"}, [28](#pds4434-bib-0028){ref-type="ref"}, [29](#pds4434-bib-0029){ref-type="ref"}

5. CONCLUSIONS {#pds4434-sec-0013}
==============

Most of the included studies evaluated aRMMs, and some also evaluated rRMMs. Cross‐sectional surveys were used to assess process indicators, while studies using secondary data sources were designed to assess outcome indicators. Half of the effectiveness indicators (process and/or outcome) were reported as successful; however, to draw conclusions that could be extrapolated to future RM effectiveness studies, a quantitative assessment of study results is necessary. The EU PAS Register proves to be a valuable resource for identifying studies evaluating the effectiveness of RMMs in Europe. It shows the impact of GVP legislation on transparency, and it is likely to stimulate further discussions in this field. This review provides valuable information to further define areas where guidance for the design, methods, interpretation, and use of data sources are required to conduct RM effectiveness studies with high quality standards.
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Figure S1. Most frequently included European Union countries in cross‐sectional surveys evaluating the effectiveness of risk minimization measures.
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Figure S2. Most frequent European Union countries for risk minimization effectiveness studies using secondary data sources.

###### 

Click here for additional data file.

We thank EpiMed Communications Ltd (Oxford, United Kingdom) for editorial assistance.
